(Q45188956)

10 December 2017

title

Combined dietary and pharmacological weight management in obese hypopituitary patients (English)

1 reference

10 December 2017

0 references

3

1 reference

10 December 2017

4

Arne Astrup

1 reference

10 December 2017

5

Ulla Feldt-Rasmussen

1 reference

10 December 2017

1

Henriette Mersebach

1 reference

10 December 2017

2

Marianne Klose

1 reference

10 December 2017

publication date

1 November 2004

1 reference

10 December 2017

1 reference

10 December 2017

volume

12

1 reference

10 December 2017

issue

11

1 reference

10 December 2017

page(s)

1835-1843

1 reference

Premature mortality due to cardiovascular disease in hypopituitarism

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Growth hormone deficiency and vascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Abnormal sympathoadrenal activity, but normal energy expenditure in hypopituitarism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Sibutramine for compulsive eating in hypothalamic deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Sibutramine: a novel new agent for obesity treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

International trial of long-term dexfenfluramine in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Sibutramine. A review of its contribution to the management of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Effect of Starvation on the Production and Metabolism of Thyroxine and Triiodothyronine in Euthyroid Obese Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Thermogenic effects of sibutramine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

A short questionnaire for the measurement of habitual physical activity in epidemiological studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

When, for whom and how to use sibutramine?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

Comparison of two questionnaires with a tri-axial accelerometer to assess physical activity patterns

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.228

31 March 2020

Identifiers

DOI

10.1038/OBY.2004.228

1 reference

10 December 2017

1 reference